Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 study, paving the way for the company to discuss a path to approval with regulators.
The experimental shot, dubbed mRNA-1010, was compared with a currently approved seasonal flu vaccine from GSK called Fluarix. The results are from an interim analysis and were disclosed in a company news release Wednesday morning.
The announcement doesn’t come in time to affect this year’s flu season as the vaccine still needs to go through the regulatory approval process.